Safety and efficacy of desloratadine in chronic idiopathic urticaria in clini…

Post-marketing surveillance studies (PMSS) of medications are often mandated by authorities, provide crucial insights for health services and are useful to define the clinical profiles of therapies. Desloratadine, a non-sedating, second-generation H1-receptor antagonist, is an effective and well-tolerated treatment for chronic idiopathic urticaria (CIU).

A Pharmacokinetic Profile of Desloratadine in Healthy Adults, Including Elderly

To characterise the pharmacokinetic profile of desloratadine and its main metabolite, 3-hydroxy (3-OH) desloratadine, in a patient population representative of the population studied in the desloratadine clinical efficacy and safety studies, including the elderly

Decongestant activiy of desloratadine in controlled-allergen-exposure trials

Edition

-

ISBN/ISSN

-

Collation

-

Series Title

-

Call Number

-

Pharmacokinetics of desloratadine in children between 2 and 11 years of age

Single doses of desloratadine syrup (1.25 and 2.5 mg) were well tolerated in children 2–5 and 6–11 years old. Desloratadine exposure in children appears to be similar to that observed in adults, in whom efficacy has been established.

SERPINA1 mRNA as a Treatment for Alpha-1 Antitrypsin Deficiency

Alpha-1-antitrypsin (AAT) deficiency is a genetic disorder that produces inactive/defective AAT due tomutations in the SERPINA1 gene encoding AAT. This disease is associated with decreased activity of AAT in the lungs and deposition of excessive defective AAT protein in the liver. Currently there is no specific treatment for liver disease associated with AAT deficiency. AAT lung disease is o…

Thunderstorm asthma: revealing a hidden at-risk population

Epidemic thunderstorm asthma (ETSA) refers to large-scale acute bronchospasm events associated with thunderstorm. The most serious episode ever recorded occurred in Melbourne, Australia, in November 2016, where more than 3500 patients were treated in hospitals and 10 died. Previous work has been focused primarily on patient presentations to emergency departments. The prevalence of individuals …

SERPINA1 and MAN1B1 polymorphisms are not linked to severe liver disease in a…

Fifteen to twenty percent of alpha-1 antitrypsin deficiency patients (A1ATD) have a severe liver outcome (portal hypertension -PHT) during childhood. Since they all share the same ZZ SERPINA1 genotype and that environmental factors such as alcohol cannot be advanced, the presence of modifier genes is now well recognized. SNPs located on the SERPINA1 and MAN1B1 genes have already been tes…